How Psilocybin-Assisted Psychotherapy Works

The "psychotherapy" in psilocybin-assisted psychotherapy is widely considered the active ingredient that turns a drug experience into therapy. The drug effect lasts 4–6 hours; the therapeutic frame around it — preparation, the dosing-day clinical container, integration psychotherapy in the days and weeks after — is what most clinical models hold responsible for sustained change. This article is the therapeutic-frame deep dive, complementing What Is Psilocybin Therapy? (which covers the foundational what-is-it framing). Here we look at the two-therapist model, the non-directive presence framework, the manualized protocols developed at Imperial College, Johns Hopkins, NYU, and Compass Pathways, the standard practices around set/setting (eye shades, music, room design), the clinical role of integration sessions, trauma-informed considerations, and how ATMA CENA adapts these principles to patients accessing psilocybin via Health Canada's Special Access Program (SAP).

Key takeaways

• The clinical psilocybin-assisted psychotherapy model uses a three-phase structure: preparation (2–3 sessions), dosing (1–2 sessions, 6–8 hours each), integration (2–4 sessions).
• Two trained therapists are present during dosing in most published trial protocols (Carhart-Harris 2016, Davis 2021, Goodwin 2022, Bogenschutz 2022). Some Canadian clinical models use one therapist + medical staff.
• Non-directive presence is the core therapist stance during dosing — supportive, grounding when needed, not interpretive or active-talking. The patient's internal experience is the work.
• Eye shades, curated music, and a quiet aesthetic environment are standard. Music selection is often manualized (the "Hopkins playlist" and similar).
• Manualized therapy frameworks: Imperial College ACE (Accept-Connect-Embody) for TRD; Yale CBT manual for psilocybin-assisted treatment; Bogenschutz MET+CBT for AUD; Breitbart Meaning-Centered Psychotherapy for cancer-related distress.
• Integration sessions are where insights become change — meaning-making, behavioural commitments, relapse prevention, processing challenging content.
• Trauma-informed practice is essential — preparation includes safety planning, grounding skills, and explicit conversation about what to do with challenging content.
• ATMA CENA's clinical model adapts these principles for SAP-pathway patients in coordination with the prescribing physician.

The three-phase structure — what each phase is for

Phase 1: Preparation (2–3 sessions, 2–4 weeks)

Preparation is where therapeutic alliance is built and where the patient is equipped to navigate the dosing experience. Standard elements:

• Therapeutic alliance with the dosing team. Most trial protocols use the same therapist team across all phases — the therapists who will be present during dosing meet the patient first. This continuity is therapeutically meaningful: the patient does not encounter the dosing team for the first time at the most intense session.
• Personal history, intentions, and what's been tried. Diagnostic clarification, treatment history, current functioning, what the patient hopes the work will address. For TRD, this often includes review of antidepressant trials and prior psychotherapy. For end-of-life work, this often includes life review and existential themes.
• Set and setting orientation. What the dosing day looks like physically; music preview (in some protocols, patients sample the playlist in advance); how to manage acute anxiety if it arises; the role of eye shades and inward focus.
• Informed consent. Off-label / SAP framing, expected effects, known risks (acute hypertension, nausea, challenging experiences, rare HPPD, psychiatric exacerbation), the absolute contraindications.
• Safety planning. Emergency contacts, post-session rest plans, behavioural commitments around substances or activities, follow-up integration scheduling.

Phase 2: Dosing session (1–2 sessions, 6–8 hours each)

This is the longest and most intense phase. The detail is in What to Expect at a Psilocybin Session — here we focus on the therapist team's role during dosing.

The clinical container is structured but mostly quiet:

• Pre-dose: vitals; final medical screening; the therapy team reviews the day with the patient; patient settles into the dosing room.
• Dose administration: oral psilocybin (typically 25 mg synthetic per the Goodwin 2022 protocol; trial-specific variations).
• Onset (20–50 minutes after dose): therapists primarily quiet; patient often settles inward with eye shades and music.
• Peak (1.5–3 hours after dose): maximum experiential intensity. Therapists practice non-directive presence — physically present, energetically supportive, not actively interpreting or psychoeducating. Most published trial protocols emphasize "follow the patient's process; do not lead it."
• Comedown (3–5 hours after dose): gradual return; therapists become more conversational; brief discussion of emerging themes; patient often spontaneously begins meaning-making.
• Discharge prep: vitals; review of what came up; integration session scheduling.

Phase 3: Integration (2–4 sessions, days to weeks after dosing)

Integration is where the acute experience becomes psychological and behavioural change. Standard elements:

• Meaning-making: what arose during dosing, what was unexpected, what felt important. Therapists help patient translate experiential content into language, narrative, and action items.
• Behavioural commitments: specific changes the patient wants to make — relationships, work, lifestyle, mental-health practices. Integration translates the "I should" of the experience into "I will."
• Difficult-experience reframing: many patients have moments of fear, grief, body horror, or disorientation during dosing. Integration is where these become productive rather than just distressing.
• Relapse prevention: for indications like TRD, AUD, or recurring depression, integration includes specific planning for how the patient will navigate triggers and maintain gains.
• Spiritual and existential themes: especially for end-of-life work, integration sessions hold space for the meaning-recovery work that mystical-type experiences often catalyze.

The two-therapist model — why most trial protocols use it

Most published psilocybin trials use two trained therapists present during dosing (Carhart-Harris 2016, Davis 2021, Goodwin 2022 COMP001, Bogenschutz 2022). The rationale:

• Continuity of presence: 6–8 hours is too long for a single therapist to maintain optimal attention; two therapists allow brief breaks.
• Patient-therapist match: many protocols use male-female dyads to give the patient access to different relational valences if needed.
• Safety: a second clinical professional adds redundancy in case of medical issues or acute psychiatric distress.
• Therapeutic depth: two-therapist co-presence creates a different relational field than one-therapist; some protocols specifically rely on the presence of two non-judging witnesses for the patient's process.

Some Canadian clinical models use one therapist + medical staff (typically a physician or NP plus a nurse) rather than two clinical psychotherapists. The model varies; the underlying principle of structured presence with redundancy holds.

Manualized therapy frameworks

Different psilocybin trials have used different therapeutic manuals as the structured framework around dosing:

ACE (Accept-Connect-Embody) — Imperial College, TRD

Used in Carhart-Harris 2016 and 2021 NEJM. The framework is acceptance-based: Acceptance of present experience, Connection with the experience and the therapeutic relationship, Embodiment through somatic anchoring. Draws from acceptance and commitment therapy (ACT) traditions. Non-directive during dosing; structured during preparation and integration.

CBT and Supportive Psychotherapy — Davis 2021 Johns Hopkins

The Johns Hopkins MDD trial used a structured supportive psychotherapy with cognitive-behavioural elements. Sessions emphasize psychoeducation, expectation-setting, integration of experience with patient's stated goals.

Motivational Enhancement Therapy + CBT — Bogenschutz 2022 AUD

The Bogenschutz AUD trial paired psilocybin with 12 weeks of structured MET + CBT — the same evidence-based AUD psychotherapy used in Project MATCH. Psilocybin was added as adjunctive consolidation to a well-validated AUD psychotherapy framework.

Meaning-Centered Psychotherapy — Breitbart cancer protocol

Developed for advanced cancer patients with demoralization. Structured short-term intervention drawing on Viktor Frankl's logotherapy. The Roots to Thrive cancer / end-of-life work in Canada draws on this tradition.

Compass Pathways COMP001 / COMP360 protocol

The 25 mg COMP360 trial used a manualized approach with two therapists, eye shades, curated music, structured preparation and integration. The protocol is the basis for ongoing Phase 3 work.

The honest framing: no single manual is "the" psilocybin therapy framework. Different indications, different patient populations, and different therapeutic traditions inform different protocols. The unifying principles — three-phase structure, non-directive dosing presence, structured integration — are stable across trials.

Set and setting — the non-pharmacological active ingredients

The Hartogsohn 2016 framework (and earlier Leary, Metzner, Alpert work) established that psychedelic effects are heavily modulated by set (the patient's mindset, expectations, history) and setting (the physical and relational environment of dosing). Clinical psilocybin therapy operationalizes this:

• Physical environment: a warm, aesthetically curated room — not a clinical examination room. Soft lighting, comfortable reclining couch or bed, blanket, small fresh flowers in some clinics. Avoiding stark medical environments where possible.
• Music: curated playlists are standard. The "Hopkins playlist" (developed at Johns Hopkins) is widely used or adapted; Compass Pathways developed its own playlist for COMP360 protocols. Music selection is part of the therapeutic frame, not background.
• Eye shades: most protocols use eye shades during the peak of the experience to deepen inward focus. Patients may remove them during comedown.
• Therapeutic alliance: the "set" the therapy team brings to the room — calm, present, non-judgmental, comfortable with intense experience — is part of the active therapy.
• Patient preparation: walking the patient through what the day will look like, including the music and physical setup, before dosing day reduces anxiety and supports the dosing experience.

Trauma-informed practice

Many patients pursuing psilocybin SAP have trauma history that informs preparation, dosing, and integration. Trauma-informed psilocybin work involves:

• Preparation that explicitly addresses trauma history. What's known, what's been processed, what hasn't. The patient and therapy team agree on how to navigate trauma content if it surfaces during dosing.
• Safety and grounding skills before dosing. Breath, somatic anchoring, orientation to the room. Patients learn these in preparation so they have access during peak intensity.
• Non-directive but available presence during dosing. Therapists do not push patients toward trauma content; they hold space if it arises.
• Integration that paces re-entry. Trauma content surfaced during dosing is processed gradually in integration, not crammed into a single session.
• Coordination with ongoing trauma therapy. Many patients pursuing psilocybin work continue with their established trauma therapist via coordinated care.

For trauma-related psilocybin work, see Psilocybin Therapy for End-of-Life Distress and the cross-cluster Ketamine Therapy for PTSD.

How ATMA CENA adapts these principles for Canadian SAP-pathway patients

ATMA CENA's clinical model integrates these therapeutic-frame principles within the SAP-pathway constraints:

• Preparation and integration in coordination with the prescribing physician. The medical SAP application is initiated by the patient's prescribing physician or psychiatric consultant. ATMA CENA's clinical team supports the psychotherapy wraparound around dosing.
• The coordinated care model lets the patient's existing therapist remain the primary therapeutic relationship; ATMA CENA's clinical infrastructure provides structure specific to the dosing experience. This is particularly relevant where patients have existing long-term therapeutic alliances.
• ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work using frameworks consistent with the published manualized protocols (preparation/integration structure, non-directive presence, set/setting). For training detail, see Psychedelic Therapy Training in Canada.
• ATMA CENA's three-phase psychedelic-assisted therapy model — preparation, dosing support coordination, integration — adapts to psilocybin work where SAP authorization is in place, with adjustments for the longer (6–8 hour) dosing day relative to ketamine.

Frequently asked questions

Why is the therapy considered the active ingredient? Because the drug effect lasts 4–6 hours but the structured frame around it — preparation, dosing-day container, integration — is what most clinical models hold responsible for sustained therapeutic change. The acute experience without integration is unlikely to produce durable change.

Do I have one therapist or two? Most published trial protocols use two trained therapists present during dosing. Some Canadian clinical models use one therapist + medical staff. Either way, structured presence with clinical safety redundancy is the principle.

What does the therapist do during dosing? Non-directive presence — physically and emotionally available, supportive, grounding when needed, not actively interpreting or psychoeducating. The patient's internal experience is the work; the therapist holds space for it.

Why eye shades and music? Eye shades support inward focus during peak intensity. Curated music is part of the therapeutic frame, not background — selected to support the arc of the experience. The "Hopkins playlist" is widely used or adapted.

What if I have trauma history? Preparation explicitly addresses trauma history and safety planning. Patients learn grounding skills before dosing. Therapists are available but non-directive during dosing. Integration paces re-entry. Coordination with ongoing trauma therapy via coordinated care is appropriate.

Do all psilocybin trials use the same therapy framework? No. Different trials use different manualized frameworks (Imperial ACE, Davis CBT-supportive, Bogenschutz MET+CBT for AUD, Breitbart Meaning-Centered for cancer). The unifying principles — three-phase structure, non-directive dosing presence, structured integration — are stable across trials.

How is integration different from regular psychotherapy? Integration sessions specifically focus on translating the dosing experience into psychological and behavioural change. They lean into experiential content (what arose, what felt important, what was unexpected) and connect it to the patient's stated goals and life situation.

How many integration sessions are typical? Trial protocols use 2–4 integration sessions. Some patients benefit from longer ongoing integration with their existing therapist; the coordinated care model supports this.

What if I had a difficult experience during dosing? Difficult experiences are common and often productive. Integration is where challenging content gets reframed and integrated. Therapists trained in psychedelic-assisted work are specifically prepared to work with difficult content.

Can my regular therapist be involved? Yes — through coordinated care model. Your existing therapist can remain the primary therapeutic relationship while ATMA CENA's clinical infrastructure provides the dosing-specific frame. This is particularly valuable for patients with established long-term therapeutic alliances.

How does ATMA CENA's training program prepare clinicians? ATMA CENA's psychedelic-assisted therapy training program covers preparation/integration structure, non-directive dosing presence, set/setting, manualized framework familiarity, and trauma-informed practice. See Psychedelic Therapy Training in Canada.

Sources

1. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
2. Carhart-Harris RL, et al. (2016). Psilocybin with psychological support for TRD: open-label feasibility. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/27210031/
3. Davis AK, et al. (2021). Psilocybin-assisted therapy for MDD: RCT. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33146667/
4. Carhart-Harris RL, et al. (2021). Psilocybin vs escitalopram for depression. NEJM. https://pubmed.ncbi.nlm.nih.gov/33852780/
5. Goodwin GM, et al. (2022). COMP360 psilocybin in TRD Phase 2b. NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
6. Bogenschutz MP, et al. (2022). Psilocybin-assisted therapy for AUD: RCT. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625
7. Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
8. Roseman L, Nutt DJ, Carhart-Harris RL (2018). Quality of acute experience predicts efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
9. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles

• Psilocybin Therapy in Canada
• What Is Psilocybin Therapy?
• What to Expect at a Psilocybin Session
• Psilocybin Side Effects and Safety
• How to Access Psilocybin Therapy in Canada (SAP)
• Psychedelic Therapy Training in Canada
• Find care near you

Last updated: 2026-05-06